Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
MelanomaProstate CancerRenal Cancer
Interventions
DRUG

Naltrexone

"4.1 Low Dose Naltrexone (LDN) LDN, 5 mg/day, at approximately 9pm, on an empty stomach, until disease progression, unacceptable toxicity, need for initiation of narcotic analgesia, or removal from protocol treatment according to section 12.0. (1 cycle = 28 days).~LDN, 5mg/ml, will be prepared by the Lifespan hospital pharmacy for patient use for this study."

Trial Locations (1)

02912

Miriam Hospital, Providence

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Brown University

OTHER

NCT01650350 - Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer | Biotech Hunter | Biotech Hunter